Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CTX131

Cell therapy (CAR-T) · Kills target cells, directed at CD70 · developed by CRISPR Therapeutics

Phase 1 Most advanced trial (none active)
CRSP Developer
1 Registered trials

What is CTX131?

CTX131 is an allogeneic T-cell therapy in which donor T lymphocytes are gene-edited with CRISPR-Cas9 to disrupt endogenous TCR and MHC class I expression and engineered to express a chimeric antigen receptor specific for CD70. The CAR T-cells recognize and bind CD70-overexpressing tumor cells, leading to cytotoxic T-lymphocyte-mediated killing. It is being studied in T cell lymphoma, B cell lymphoma, and acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD70 (antigen), T-cell receptor (TCR) (secondary target), MHC class I molecules (secondary target)
Mechanism
Kills target cells, directed at CD70
Pathways
CTL-mediated killing of CD70-positive tumor cells, CD27 costimulatory signaling
Therapy area
Oncology
Developer
CRISPR Therapeutics AG (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06492304 Phase 1 T Cell Lymphoma Completed CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaB Cell LymphomaT Cell Lymphoma

Other drugs acting on CD70

More from CRISPR Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind CTX131

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.